Targeting IGF‐1/IGF‐1R signaling has been explored as a therapeutic strategy, with IGF‐1R inhibitors showing potential in insulin‐resistant cancers, particularly in breast, colorectal, and prostate cancer [22, 84]. Here, IGF1R is linked to prostate cancer.